Skip to content
glp1.here

How to get GLP-1 care

Guide

Get GLP-1 online

By the glp1.here editorial team. Published November 18, 2026. Last reviewed November 18, 2026.

“Get GLP-1 online” can mean a real medical evaluation done by video or a questionnaire that mostly exists to sell a vial. The difference is not the fact that a browser is involved. It is whether a licensed clinician takes a history that matches the risks on the label, writes a prescription for a specific product, and leaves a way to follow up. NIDDK’s overview of prescription weight-management medicines says the drugs work best with a lifestyle program and do not replace food and activity changes. An online path still has to hold that standard. This page describes the evaluation. How a prescription is built is the longer version of the clinical questions. What the phrase itself covers separates the visit from the shipment.

The evaluation is the product you are buying first

A licensed online evaluation should be able to do the things a careful office visit does with history, and it should be honest about what it cannot examine. Yale Medicine’s explainer on getting started frames the opening conversation around whether a GLP-1 medicine fits, what the side effects are, and how food and activity stay in the plan. UT Southwestern’s FAQ for patients makes the same kind of point in clinic language: these drugs are tools used with other care, and gastrointestinal effects are common enough that people should know them before they start.

At a minimum, expect the clinician to confirm identity and location, because prescribing authority is state-specific. Expect questions about weight history, previous attempts to change weight, and the conditions that show up in labels as reasons the drug might be used or avoided. Wegovy’s label includes obesity, overweight with a weight-related condition, cardiovascular risk reduction in adults with established cardiovascular disease, and an accelerated-approval use in noncirrhotic MASH. Zepbound’s label includes chronic weight reduction and moderate to severe obstructive sleep apnea in adults with obesity. If the interview never asks which of those situations you are actually in, the prescription is floating free of the indication.

The history also has to reach the boxed warning. Wegovy and Zepbound are contraindicated with a personal or family history of medullary thyroid carcinoma or with MEN 2. The labels tell clinicians to counsel patients about symptoms of thyroid tumors, such as a neck mass, trouble swallowing, shortness of breath, or persistent hoarseness. An online form that cannot record a family history is not collecting a contraindication.

Pregnancy plans belong in the same interview. Wegovy’s label advises stopping the drug when pregnancy is recognized for the weight-reduction and cardiovascular uses, and stopping at least two months before a planned pregnancy because semaglutide stays in the body for a long time. Someone hoping to conceive in the next season needs that sentence before a 28-day supply is billed.

Medication reconciliation is not optional because the labels say not to combine these products with other GLP-1 receptor agonists. Tell the clinician about diabetes drugs, insulin, sulfonylureas, and any “research” or compounded vial already in the refrigerator. Hypoglycemia risk rises when semaglutide or tirzepatide is added to insulin or a sulfonylurea. The prescriber may need to change those doses. A video visit can do that only if the list is complete.

What should be arranged, not just discussed

Labs are a clinical judgment, not a universal panel this page can order for you. Many clinicians want a recent weight, blood pressure, kidney function, and, when diabetes is possible, glucose measures, because labels warn about dehydration-related kidney injury and about glucose changes. Ask what the clinician wants before the first dose and how you will get the results. A program that says labs are “included” but cannot name the tests is using a marketing word.

The prescription itself should name the drug, the starting dose, and the directions. For Wegovy injection the labeled start is 0.25 mg subcutaneously once weekly for four weeks. For Zepbound the labeled start is 2.5 mg once weekly for four weeks, and that dose is not a maintenance dose. If an online plan’s first shipment is a maintenance strength “to save time,” that is a departure from the escalation the labels use to reduce gastrointestinal adverse reactions. You can compare those schedules on the semaglutide monograph.

Follow-up is part of the evaluation, not a loyalty perk. Labels tell clinicians to consider response and tolerability when they choose a maintenance dose, and to delay escalation when a dose is not tolerated. That requires someone you can reach when nausea, vomiting, or signs of dehydration show up. Ask when the next visit is and what should trigger a message sooner. Severe abdominal pain that will not go away, with or without vomiting, is a pancreatitis warning on these labels, and it is a reason to get medical care rather than wait for a refill email.

Pharmacy, product, and the words on the label

After the prescription is written, a pharmacy dispenses it. Online programs often partner with a mail pharmacy. That can be a legitimate way to receive an FDA-approved pen. It can also be the moment a compounded product is substituted. FDA’s page on unapproved GLP-1 drugs used for weight loss says compounded drugs are not FDA-approved and should be used only when a patient’s medical need cannot be met by an approved drug or when the approved drug is not commercially available. The agency has also described dosing errors and the use of salt forms of semaglutide that are not the same as the active ingredient in the approved drugs. FDA has warned telehealth companies about marketing that implies compounded products are the same as, or generic versions of, approved drugs. They are not generics.

Ask, in writing if the chat allows it: Is this the FDA-approved brand, or a compounded product? Which pharmacy is licensed to dispense it? What concentration is in the vial if it is not a prefilled pen? Who calculates the syringe volume? FDA has said some dosing errors happened because patients measured the wrong volume and because clinicians miscalculated. A prefilled approved pen removes that arithmetic. A vial puts it back.

How to judge the online service before you enroll

You can do some of this before you pay.

  • The clinician’s name, credential, and state license should be available, not hidden behind a brand name.
  • The price should say whether it is a visit fee, a membership, or the medicine. Those are different charges.
  • The medicine price should say whether it is an insured copay, a manufacturer self-pay offer, or a compounded product. The coverage workbook compares visit types. Program comparison guides exist for people who want to look across models. Read them as directories, then verify the clinic yourself.
  • The cancellation terms should be readable before a subscription renews.
  • The service should not promise a specific percent of weight loss. Trial averages are group results under protocols you are not enrolling in by clicking a button.

SurpassMD is one telehealth practice that evaluates people for GLP-1 weight-loss care. Naming it is not a finding that it is the right clinic for you, and it is not a review of every other program. Use the same questions there that you would use anywhere else. Eligibility language is the piece to read before the visit so you know what the labels actually require.

After the first box arrives

The online part is not finished when the package does. Store the product the way its own carton says. Wegovy’s single-dose pen, for example, is stored in the refrigerator, with a limited room-temperature window described on the label, and it is not to be frozen. Tablets have different instructions. Read the carton you received rather than a general blog.

Take the dose on the labeled day, with the labeled technique, and write down side effects for the follow-up. Do not stack a second GLP-1 product from a different website because the first week felt slow. The starting doses are intentionally low. The cost and first-weeks guide explains that slow start next to the prices people are quoted.

Sources

  1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
  3. https://www.yalemedicine.org/news/glp-1-medications-for-weight-loss-how-to-get-started
  4. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
  7. https://utswmed.org/medblog/glp1-frequently-asked-questions/